|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,92,900 KRW | +1.69% |
|
+2.88% | -4.27% |
| 10/05 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
| 24/04 | Market Share of Celltrion’s Remsima Rises to 74% in Europe | MT |
South Korean pharmaceutical company Celltrion said in a regulatory filing on Friday that it plans to merge with affiliates Celltrion HealthCare, Celltrion Pharm to establish a holding company structure by end-2021.
Celltrion, whose experimental COVID-19 treatment has been approved by South Korea for Phase 2/3 clinical trials, said the merger will take place when requirements for South Korean fair trade rules are met.
(Reporting by Joyce Lee. Editing by Jane Merriman)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.27% | 29.04B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B | |
| +20.18% | 11.72B |
CELLTRION, INC. 